The FDA said accurate information comparing a biosimilar and its reference product could be considered misleading if offered in the wrong context • Source: Shutterstock
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
